| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -86.7 | -812.7 |
| EPS (diluted, $ a share) | $-1.45 | $-121.63 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: VOR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vor Biopharma Inc.: key numbers
- Share price
- $18.97Close, Nov 16
- Market cap
- $1.17B
- Shares outstanding
- 61.43MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vor Biopharma Inc.
All →Vor Biopharma Licensing Deal with RemeGen Co., Ltd. Worth $10M
Vor Biopharma expanded its existing partnership with RemeGen by entering into an amended and restated license agreement to add RC298, a next-generation dual BAFF/APRIL inhibitor, to its exclusive development and commercialization rights outside of Greater China. Vor Bio will pay an upfront cash payment of $10 million and issue a pre-funded warrant for 2.3 million shares, with RemeGen eligible for up to $630 million in development and regulatory milestones plus tiered royalties.
- Value
- $10M
- Counterparty
- RemeGen Co., Ltd.